Previous studies demonstrated that CysLts have a clear role in the occurrence of pathophysiological conditions, such as asthma, AR, and other nasal allergies.21, 33, 34 A study by Figueroa et al.35on the mRNA and protein expression of CysLT1 and CysLT2 receptors in inflammatory cells from nasal lavage samples collected from participants during active SAR demonstrated that CysLT1 receptor-positive cells were highly responsible for the development of inflammation, which indicates the potential of CysLT antagonists in treating both AR and asthma. The gene discussed is CYSLTR1; the disease is asthma.